AC Immune SA (ACIU)
2.49
+0.01
(+0.40%)
USD |
NASDAQ |
May 01, 16:00
AC Immune Enterprise Value: 123.57M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 123.57M |
| April 30, 2024 | 122.58M |
| April 29, 2024 | 114.67M |
| April 26, 2024 | 109.73M |
| April 25, 2024 | 103.79M |
| April 24, 2024 | 111.71M |
| April 23, 2024 | 112.70M |
| April 22, 2024 | 116.65M |
| April 19, 2024 | 110.72M |
| April 18, 2024 | 112.70M |
| April 17, 2024 | 116.65M |
| April 16, 2024 | 119.62M |
| April 15, 2024 | 126.54M |
| April 12, 2024 | 148.30M |
| April 11, 2024 | 147.31M |
| April 10, 2024 | 154.23M |
| April 09, 2024 | 154.23M |
| April 08, 2024 | 154.23M |
| April 05, 2024 | 149.29M |
| April 04, 2024 | 149.29M |
| April 03, 2024 | 154.23M |
| April 02, 2024 | 144.34M |
| April 01, 2024 | 147.31M |
| March 28, 2024 | 170.06M |
| March 27, 2024 | 176.98M |
| Date | Value |
|---|---|
| March 26, 2024 | 158.19M |
| March 25, 2024 | 164.12M |
| March 22, 2024 | 180.94M |
| March 21, 2024 | 188.85M |
| March 20, 2024 | 199.23M |
| March 19, 2024 | 209.62M |
| March 18, 2024 | 223.46M |
| March 15, 2024 | 223.46M |
| March 14, 2024 | 206.65M |
| March 13, 2024 | 244.35M |
| March 12, 2024 | 224.51M |
| March 11, 2024 | 216.57M |
| March 08, 2024 | 252.28M |
| March 07, 2024 | 262.20M |
| March 06, 2024 | 262.20M |
| March 05, 2024 | 269.15M |
| March 04, 2024 | 238.40M |
| March 01, 2024 | 259.23M |
| February 29, 2024 | 236.41M |
| February 28, 2024 | 265.18M |
| February 27, 2024 | 253.28M |
| February 26, 2024 | 251.29M |
| February 23, 2024 | 218.56M |
| February 22, 2024 | 202.68M |
| February 21, 2024 | 208.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.6107M
Minimum
Dec 22 2022
413.52M
Maximum
Jan 15 2020
167.46M
Average
149.10M
Median
Oct 17 2023
Enterprise Value Benchmarks
| CRISPR Therapeutics AG | 2.872B |
| Addex Therapeutics Ltd | 4.065M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -95.36M |
| MoonLake Immunotherapeutics | 2.199B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.353M |
| Revenue (Quarterly) | 16.70M |
| Total Expenses (Quarterly) | 20.70M |
| EPS Diluted (Quarterly) | -0.0564 |
| Profit Margin (Quarterly) | -32.05% |
| Earnings Yield | -28.49% |
| Normalized Earnings Yield | -28.50 |